Biogen Acquires Nightstar Therapeutics in $800 Million Gene Therapy Deal

Health care giant Biogen has announced plans to acquire gene therapy company Nightstar Therapeutics. In a statement on Monday, Biogen said that it will acquire Nightstar for $25.50 per share pending customary closing conditions. The deal, which values Nightstar at $800 million after expenses, is an all-cash acquisition that will give Biogen a foothold in […]